Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 01:15AM GMT
Eric Joseph JPMorgan Chase;Co.;Analyst

&-

I am Eric Joseph, senior biotech analyst at JPMorgan and our next presenting company is Novavax. Presenting on behalf of the company is CEO, John Jacobs. There is going to be a Q&A session after the presentation. So just raise your hand, we'll bring a mic around for those who have questions. And for those tuning in via webcast, you can submit questions there as well. So with that, John.

John Jacobs
Novavax Inc - President, Chief Executive Officer, Director

Thank you, Eric. Good evening everyone. Thank you for joining us tonight at this late hour. So we're probably standing between you and dinner and a cocktail or for some of you that I know maybe a good cigar and that kind of thing. But really appreciate you joining us this evening.

I'm CEO of Novavax, John Jacobs, and I'm joined tonight by several colleagues who will be joining me for the Q&A session. Dr. Filip Dubovsky, our President of R&D; John Trizzino, our President and Chief Operating Officer; and Jim Kelly, our CFO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot